Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is a pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products.
Business. Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049.HK) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in Jilin Province, China, and operates within the broader pharmaceuticals and medical research sector. It is primarily listed on the Hong Kong Stock Exchange under the ticker symbol 8049.HK. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049.HK) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in Jilin Province, China, and operates within the broader pharmaceuticals and medical research sector. It is primarily listed on the Hong Kong Stock Exchange under the ticker symbol 8049.HK. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd maintains a conservative capital structure with a price-to-book ratio of 0.8 and a debt-to-equity ratio of 0.0, indicating minimal leverage. The company's liquidity position is strong, with a current ratio of 1.3 and cash and equivalents of 143.1 million CNY, which supports operational flexibility. The market capitalization of 1.34 billion CNY and a price-to-earnings ratio of 6.76 suggest the stock is trading at a discount relative to earnings.
The company's profitability is robust, with a return on equity of 11.78% and a return on assets of 7.45%, both exceeding the typical thresholds for the pharmaceutical industry. Gross profit of 757.67 million CNY and operating income of 265.85 million CNY reflect strong cost control and pricing power. However, the net income of 198.88 million CNY is lower than the gross profit, indicating some pressure on operating expenses or taxes.
Geographic and segment exposure data is not available in the provided input, but the company's revenue of 901.87 million CNY is likely concentrated in its domestic operations given the lack of international revenue breakdown. The absence of detailed segment reporting limits the ability to assess diversification or growth drivers within the business.
The company's growth trajectory is modest, with no specific revenue or earnings growth projections provided in the input data. Analyst estimates for the last actual EPS and revenue are 0.02 CNY and 97.28 million CNY, respectively, which are slightly below the reported figures, suggesting a stable but not rapidly growing business. The free cash flow of 96.17 million CNY and capital expenditure of -12.45 million CNY indicate that the company is generating positive cash flow and may be reducing investments in physical assets.
Risk factors for the company are minimal, with low liquidity and dilution risks identified. No immediate filing-based liquidity or dilution flags were detected, and the company's capital structure remains stable. The absence of significant debt and the presence of substantial cash reserves reduce the likelihood of financial distress.
Recent events and filings do not show any material changes in the company's operations or financial condition. The lack of recent significant events or disclosures suggests a stable and predictable business environment. The company's financial performance and risk profile remain consistent with its historical trends.
- The company has a strong liquidity position with a current ratio of 1.3 and significant cash reserves.
- Profitability metrics such as return on equity and return on assets are above industry norms.
- The company's capital structure is conservative, with no long-term debt and a low debt-to-equity ratio.
- Growth projections are limited, and the company appears to be maintaining a stable business model.
- Risk factors are minimal, with no immediate liquidity or dilution concerns.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Jilin Province Huinan Changlong Bio-pharmacy Co Ltd Market data — financials · 2026-05-27
- Jilin Province Huinan Changlong Bio-pharmacy Co Ltd Market data — analyst estimates · 2026-05-27